Lebanon

Reimbursed Care Access

Lebanon maintains a conventional medical/regulatory approach: ketamine and the esketamine product Spravato are registered with the Ministry of Public Health and are available for medical use in healthcare settings, while classical serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, ayahuasca), ibogaine and 2C‑X family substances have no authorized routine medical program and are treated as controlled/illicit substances outside of regulated research or criminal enforcement. Public reimbursement for high-cost specialty psychiatric products is limited; availability is primarily via registered hospital pharmacies or private clinics and often without broad public subsidy. [https://www.moph.gov.lb/en/Drugs/index/0/10256/page%3A158|Lebanese Ministry of Public Health — National Drugs Database].